In terms of lymph node metastases (LNM) before first adjuvant therapy, clinically detectable LNM outnumbered occult LNM with 18 patients (52.9%) under PD‐1 and 15 patients (46.9%) under BRAF + MEK therapy. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.